Chugai Pharmaceutical Co., Ltd.

TSE:4519 Voorraadrapport

Marktkapitalisatie: JP¥11.6t

Chugai Pharmaceutical Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Chugai Pharmaceutical is de winst gegroeid met een gemiddeld jaarlijks percentage van 16.3%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 3.4%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 12% per jaar. Het rendement op eigen vermogen van Chugai Pharmaceutical is 21.5%, en het heeft een nettomarge van 33.9%.

Belangrijke informatie

16.3%

Groei van de winst

16.3%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie3.4%
Inkomstengroei12.0%
Rendement op eigen vermogen21.5%
Nettomarge33.9%
Volgende winstupdate30 Jan 2025

Recente prestatie-updates uit het verleden

We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

May 01
We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

Recent updates

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Oct 30
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next

Oct 29
Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Oct 15
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Should You Be Adding Chugai Pharmaceutical (TSE:4519) To Your Watchlist Today?

Oct 12
Should You Be Adding Chugai Pharmaceutical (TSE:4519) To Your Watchlist Today?

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Sep 24
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Jul 30
Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00

Jul 27
Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00

Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Jul 15
Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00

Jun 19
Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Jun 17
Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

May 04
Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

May 01
We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apr 26
Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

Mar 01
Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

Opbrengsten en kosten

Hoe Chugai Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TSE:4519 Opbrengsten, kosten en inkomsten (JPY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 241,142,350386,964108,439171,068
30 Jun 241,084,570355,041108,201171,722
31 Mar 241,036,076326,373114,150173,356
31 Dec 231,111,367325,472112,580174,868
30 Sep 231,276,051336,745112,702178,244
30 Jun 231,243,437326,969107,753169,379
31 Mar 231,211,632316,15496,519158,627
31 Dec 221,259,946374,429100,760149,626
30 Sep 221,143,716370,791104,720142,201
30 Jun 221,205,696389,011106,839141,695
31 Mar 221,191,496387,359107,887141,438
31 Dec 21999,759302,995102,416137,299
30 Sep 21887,919256,46298,992132,324
30 Jun 21809,055230,57796,489126,265
31 Mar 21776,339210,61194,546121,477
31 Dec 20786,946214,73394,401117,850
30 Sep 20753,853202,59095,497116,049
30 Jun 20734,019190,59996,919110,994
31 Mar 20711,320174,062102,068108,903
31 Dec 19686,184157,560101,574107,942
30 Sep 19662,198139,54399,844105,231
30 Jun 19614,949113,07097,895102,491
31 Mar 19586,64899,63192,37999,289
31 Dec 18579,78792,48893,41699,202
30 Sep 18572,99485,85791,55398,150
30 Jun 18566,54885,28589,71096,639
31 Mar 18556,15982,10189,63198,744
31 Dec 17534,19972,71388,14792,947
30 Sep 17517,90867,70482,41190,427
30 Jun 17497,02358,14382,46589,728
31 Mar 17497,35457,59281,24885,000
31 Dec 16491,78053,59281,94185,011
30 Sep 16492,58456,56285,48183,366
30 Jun 16506,19262,53786,31384,761
31 Mar 16501,64961,04387,77284,111
31 Dec 15498,83961,12588,01883,799
30 Sep 15495,45558,89785,49285,815
30 Jun 15479,26552,22086,64883,082
31 Mar 15454,14746,78686,13481,284
31 Dec 14461,10950,98085,65580,625
30 Sep 14450,54552,46184,30575,413
30 Jun 14444,65855,04483,53576,124
31 Mar 14457,28160,77484,33676,087
31 Dec 13423,65250,89583,56672,706

Kwaliteitswinsten: 4519 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (33.9%) 4519 } zijn hoger dan vorig jaar (26.4%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 4519 is de afgelopen 5 jaar met 16.3% per jaar gegroeid.

Versnelling van de groei: De winstgroei van 4519 over het afgelopen jaar ( 14.9% ) ligt onder het 5-jarig gemiddelde ( 16.3% per jaar).

Winst versus industrie: De winstgroei 4519 over het afgelopen jaar ( 14.9% ) overtrof de Pharmaceuticals -sector 38.7%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 21.5% ) van 4519 wordt als hoog beschouwd.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y